Hologic, Inc. (NASDAQ:HOLX) Expected to Earn Q3 2025 Earnings of $1.12 Per Share

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Zacks Research lifted their Q3 2025 EPS estimates for Hologic in a research note issued to investors on Wednesday, September 4th. Zacks Research analyst M. Mondal now forecasts that the medical equipment provider will post earnings of $1.12 per share for the quarter, up from their prior estimate of $1.11. The consensus estimate for Hologic’s current full-year earnings is $4.09 per share. Zacks Research also issued estimates for Hologic’s FY2025 earnings at $4.37 EPS.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 EPS.

Several other brokerages have also recently weighed in on HOLX. Stephens reissued an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a report on Friday, August 16th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 10th. Argus upped their price objective on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.60.

Hologic Stock Performance

NASDAQ HOLX opened at $80.99 on Friday. Hologic has a fifty-two week low of $64.02 and a fifty-two week high of $84.67. The firm has a market capitalization of $18.90 billion, a P/E ratio of 41.32, a price-to-earnings-growth ratio of 2.57 and a beta of 0.99. The stock’s fifty day moving average is $79.30 and its two-hundred day moving average is $76.57. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. Norges Bank purchased a new position in shares of Hologic in the 4th quarter valued at about $217,529,000. Price T Rowe Associates Inc. MD lifted its stake in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. Swedbank AB acquired a new position in Hologic during the 1st quarter worth approximately $120,827,000. The Manufacturers Life Insurance Company increased its position in shares of Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after purchasing an additional 1,168,564 shares during the last quarter. Finally, Black Creek Investment Management Inc. raised its holdings in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Hologic

In related news, insider Brandon Schnittker sold 476 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last ninety days. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.